IGF-1 LR3
IGF-1 LR3 is a modified, long-acting analog of insulin-like growth factor 1, engineered to resist the body's IGF-binding proteins and remain active longer than natural IGF-1.
- An extended half-life IGF-1 analogue
- Associated with muscle protein synthesis in research
- Studied for recovery support
No commitment · Cancel anytime · Physician evaluation required
About IGF-1 LR3
IGF-1 is a hormone produced largely in response to growth hormone signaling, mediating much of GH's tissue-building effects. IGF-1 LR3 modifies the natural molecule with an extended B-chain and a substituted amino acid, reducing its binding to IGF-binding proteins and extending its active half-life significantly beyond native IGF-1.
What the research shows
IGF-1's biology as a driver of muscle protein synthesis and tissue growth is well characterized in endocrinology. However, IGF-1 LR3 specifically is a modified research compound: published human clinical trial data on its use for muscle building or recovery in healthy adults is limited, with most available evidence coming from animal and cell-culture research rather than controlled human trials.
Who it's for
IGF-1 LR3 is generally considered by adults interested in muscle and recovery support as part of a broader performance-focused program, understanding this compound has a thinner direct human trial base than several other options in this catalog.
How It's Administered
IGF-1 LR3 is typically administered as a subcutaneous injection, often timed around training, on a schedule your physician determines during your evaluation.
Safety & Considerations
Because IGF-1 pathway activation affects cell growth broadly, monitoring is an important part of physician-supervised use. Reported effects can include hypoglycemia (since IGF-1 has insulin-like activity) and injection site reactions.
Your physician will review your full health history during your evaluation, and this program is not appropriate for everyone.
Selected References
The following peer-reviewed sources informed the summary above. Evidence quality varies — some reflect large controlled human trials, others early-stage or animal research, as noted.
- Pep-Pedia: Peer-Reviewed Peptide Research Platform — IGF-1 LR3 overview
Pep-Pedia research summary